Search

Captures ECG and heart rate as a response to treatment for heart, lung, and health problems CAMPBELL, Calif., Feb. 16, 2021 /PRNewswire/ -- VivaLNK, a leading provider of connected healthcare [...]

CS Fallback, Dropped Call Rates, Data KPIs and more measured CARDIFF, Wales, December 10, 2012 /PRNewswire/ -- Epitiro today announces the release of its latest ipQ[TM] LTE test solution that [...]

SOUTH PLAINFIELD, N.J., Dec. 8 /PRNewswire/ -- Data published online in the medical journal Muscle and Nerve support the use of the six-minute walk test (6MWT) as an outcome measure [...]

- Findings Suggest Clinically Meaningful Primary Endpoint for Clinical Trials; Data Presented at the 13th International World Muscle Society Congress - SOUTH PLAINFIELD, N.J., Sept. 30 /PRNewswire/ -- PTC Therapeutics, [...]

>80 Meter Improvement in the Primary Endpoint of 6 Minute Walk Test (6MWT) at 48 Weeks of Exposure Compared to Natural History (p =0.0005) Elamipretide Achieves Statistical Significance on Key [...]

Primary endpoints of six-minute walk test and Primary Mitochondrial Myopathy Symptom Assessment (PMMSA) Total Fatigue Score not met FDA engagement for Barth syndrome and enrollment of Phase 2 trial in [...]

Lab Will Leverage VIAVI Automated Lab-as-a-Service (VALOR(TM)) and is Funded by the U.S. Agency For International Development (USAID) CHANDLER, Ariz., Oct. 29, 2024 /PRNewswire/ -- https://c212.net/c/link/?t=0&l=en&o=4288387-1&h=2326434466&u=https%3A%2F%2Fwww.viavisolutions.com%2F&a=VIAVI+Solutions+Inc.(VIAVI) (NASDAQ: VIAV) today announced [...]

WASHINGTON, Oct. 28, 2024 /PRNewswire/ -- MitrAssist Lifesciences, a leader in innovative cardiovascular medical devices, today unveiled the initial clinical results of its groundbreaking new product, SIKELIA(TM), during the 2024 [...]

NAPERVILLE, Ill., Sept. 28, 2024 /PRNewswire/ -- Endotronix, an Edwards Lifesciences company (NYSE: EW), today announced the one-year clinical results from PROACTIVE-HF, evaluating outcomes for the Cordella Pulmonary Artery (PA) [...]

Tirzepatide reduced the risk of heart failure outcomes -- heart failure urgent visit or hospitalization, oral diuretic intensification or cardiovascular death -- by 38% compared to placebo Tirzepatide significantly improved [...]

Zilganersen is the first investigational medicine in clinical development for people with Alexander disease, a rare, life-threatening neurological condition CARLSBAD, Calif., July 18, 2024 /PRNewswire/ -- https://c212.net/c/link/?t=0&l=en&o=4213943-1&h=1695383120&u=https%3A%2F%2Fwww.ionis.com%2F&a=Ionis+Pharmaceuticals%2C+Inc.(Nasdaq: IONS) announced today [...]

ZUG, Switzerland, June 17, 2024 /PRNewswire/ -- The Berlin Heals Holding AG has developed the C-MIC device, a revolutionary and life-saving treatment for patients with heart failure (DCM / dilated [...]

The trial met primary safety and efficacy endpoints, demonstrating a markedly low rate of heart failure hospitalizations for NYHA class III HF patients. The results support the company's pre-market approval [...]

Recent updates on its development of LSD treatments were presented YONGIN, South Korea, Feb. 14, 2024 /PRNewswire/ -- GC Biopharma (CEO, Eun-Chul Huh), a South Korean biopharmaceutical company, announced on [...]

--Systemic Sclerosis (SSc) Patient Data Shows High Serum CCL24 Levels Associated with More Severe Manifestations of Disease, Including Pulmonary Arterial Hypertension -- -- Study Reveals that CCL24 Activates Endothelial Cells [...]

First-in-human trial of AB-1002 designed to establish safety and preliminary efficacy in patients with NYHA Class III Heart Failure Heart failure is a leading cause of morbidity and mortality worldwide [...]

LAS VEGAS, Nov. 1, 2023 /PRNewswire/ -- The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research, announces the results [...]

Clario's Precision Motion Opal wearable sensor technology detects early Parkinson's disease (PD) progression in a University of Oxford study funded by UCB Pharma. Digital endpoints of gait and balance, captured [...]

REBALANCE-HF early feasibility trial met objective of identifying responder group with demonstrated benefits in heart function, hemodynamics, and physical activity at 6 months SAVM procedure quick and easy to perform [...]

NEEDHAM, Mass., Sept. 11, 2023 /PRNewswire/ -- Stealth BioTherapeutics Inc. (the 'Company' or 'Stealth'), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies for diseases [...]

Pharmanovia Obtains Exclusive License to Commercialize Elamipretide for the Treatment of Barth Syndrome in the European Union, United Kingdom, Middle East, and Northern Africa NEEDHAM, Mass., May 30, 2023 /PRNewswire/ [...]

OR YEHUDA, Israel, March 7, 2023 /PRNewswire/ -- https://restoremedical.co/, a privately held medical device company, has successfully completed enrollment of the First In Human clinical study with its CONTRABAND(TM) device. [...]

Data presented at the 19th Annual WORLDSymposium(TM) 2023 TOKYO, Feb. 22, 2023 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., 'Astellas') today announced an update [...]

- Presentations include age of loss of ambulation and preservation of upper limb function following treatment with Translarna in patients with nonsense mutation Duchenne muscular dystrophy - SOUTH PLAINFIELD, N.J., [...]

BOSTON, Sept. 15, 2022 /PRNewswire/ -- Stealth BioTherapeutics Corp (NASDAQ: MITO), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies for diseases involving mitochondrial dysfunction, [...]

Patented complex of Boswellia serrata and Aegle marmelos can help consumers breathe easier, enhance well-being, and improve exercise capacity. MORRISTOWN, N.J., June 30, 2022 /PRNewswire/ -- PLT Health Solutions, Inc [...]

Randomized, double-blind, placebo-controlled trial found Mitopure(TM) Urolithin A improves muscle strength and exercise performance in middle-aged adults BRIDGEWATER, N.J., May 17, 2022 /PRNewswire/ -- Nestlé Health Science, a globally recognized [...]

AUSTIN, Texas, April 11, 2022 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (Nasdaq:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics to benefit people with rare metabolic diseases, [...]

Pegzilarginase BLA preparation on track to enable a second quarter 2022 submission to the FDA Accelerating Phase 1/2 trial of AGLE-177 for Homocystinuria; clinical data announcement expected in the second [...]

80% plasma arginine reduction (primary endpoint; p < 0.0001) accompanied by a positive trend in GMFM-E, a key clinical assessment of patient mobility 90.5% of patients achieved normal plasma arginine [...]

Abstracts illustrate the drivers and progression of ARG1-D including the long-term challenges faced by patients, caregivers and healthcare professionals Phase 3 PEACE study baseline characteristics provide important demographic and disease [...]

NEW YORK, Nov. 3, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Longeveron Inc. ('Longeveron' or the 'Company') (NASDAQ: LGVN) and certain of [...]

NEW YORK, Oct. 25, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Longeveron Inc. ('Longeveron' or the 'Company') (NASDAQ: LGVN) and certain of [...]

NEW YORK, Oct. 15, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Longeveron Inc. ('Longeveron' or the 'Company') (NASDAQ: LGVN) and certain of [...]

NEW YORK, Oct. 7, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Longeveron Inc. ('Longeveron' or the 'Company') (NASDAQ: LGVN) and certain of [...]

NEW YORK, Sept. 29, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Longeveron Inc. ('Longeveron' or the 'Company') (NASDAQ: LGVN) and certain of [...]

NEW YORK, Sept. 13, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Longeveron Inc. ('Longeveron' or the 'Company') (NASDAQ: LGVN) and certain of [...]

Trial led by Saint Luke's Mid America Heart Institute shows treatment with dapagliflozin results in significant improvements in symptoms, physical limitations, and exercise function for HFpEF patients KANSAS CITY, Mo., [...]

PALM BEACH, Fl., Aug. 13, 2021 /PRNewswire/ -- FinancialNewsMedia.com News Commentary - The normal aging process is characterized by a progression of physiologic events that occur throughout the life cycle. [...]

DENVER, July 29, 2021 /PRNewswire/ -- Much has been learned about SARS-CoV-2, the virus that causes the novel coronavirus, since the beginning of the COVID-19 pandemic. However, questions remain about [...]

AUSTIN, Texas, July 14, 2021 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic [...]

MECHANICSBURG, Pa., July 8, 2021 /PRNewswire/ -- Former COVID-19 patients may benefit from additional clinical support, including tailored physical and mental health rehabilitation services, according to a study released today [...]

Efficacy and safety results were based on interim analyses at week 109 from the open-label extension trial of a VILTEPSO Phase 2 study. The primary endpoint of Time to Stand [...]

- Data presented at the 2021 Parent Project Muscular Dystrophy Annual Conference - SOUTH PLAINFIELD, N.J., June 24, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today presented pooled placebo [...]

BOSTON, May 17, 2021 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies for diseases involving mitochondrial dysfunction, [...]

Topline Results Expected in the Fourth Quarter of 2021; Target Enrollment Exceeded Pegzilarginase has the Potential to be the First FDA-Approved Treatment to Address the Underlying Cause of ARG1-D, a [...]

KIRKLAND, Wash., April 7, 2021 /PRNewswire/ -- Cardiac Dimensions announced a published second individual patient data meta--analysis demonstrating clinically significant outcomes for the Carillon Mitral Contour System. This publication, in [...]

Type B meeting scheduled with FDA Division of Cardiology and Nephrology Management to host conference call tomorrow at 8:30am ET BOSTON, Jan. 5, 2021 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: [...]

BOSTON, Dec. 9, 2020 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, [...]

Satera(TM) Ablation System demonstrates success as a frontline treatment of heart failure NEW YORK, Oct. 9, 2020 /PRNewswire/ -- Axon Therapies, a Coridea portfolio company focused on addressing one of [...]